Mar. 2 at 7:28 PM
$ASRT Maybe Q4 nos are good, Hanmi released its earnings, notable mentions which suggests maybe its not 5m as we anticipate.
This is the result of increased clinical materials supply to partner companies, inflow of upfront payments from Gilead Sciences, and increased royalty income from Rolvedon sales, which positively contributed to the performance.
Yang-hwan Choi: Thank you for your question. The strong export performance in the separate business segment this time is due to the supply of Efinopegdutide clinical trial materials, and also reflects the impact of the announcement made by our partner company, Assertio, regarding quarterly sales related to the label change of Rolvedon.
The next page, page 8, shows the Q4 performance on a separate basis. Driven by increased sales of clinical materials and royalties from Rolvedon, sales increased by 9.1% YoY to 306.1 billion won, and operating profit increased by 86.5% to 55.5 billion won, resulting in a significant improvement in profitability
